Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

liarozole

An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits… Expand
National Institutes of Health

Related topics

Related topics

11 relations

Broader (5)

Androgen AntagonistsAntineoplastic Agents, HormonalDermatologic AgentsEnzyme Inhibitors
Expand
Liarozole HydrochlorideNCIt Antineoplastic Agent Terminologyliarozole fumarate

Narrower (3)

LiazalR 085246R 75251

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agent.
OBJECTIVE To study the influence of liarozole on leiomyoma cell proliferation and extracellular matrix (ECM) gene expression in… Expand
Is this relevant?
2007
2007
Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study.
BACKGROUND Liarozole, a retinoic acid metabolism blocking agent, has been granted orphan drug status for congenital ichthyosis by… Expand
Is this relevant?
2004
2004
Modulation of all-trans retinoic acid pharmacokinetics by liarozole
Continuous oral dosing with all-trans retinoic acid (RA) is associated with a progressive decrease in plasma drug concentrations… Expand
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2001
2001
Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
BACKGROUND Palmoplantar pustular psoriasis (PPP) is a chronic, relapsing condition often recalcitrant to therapy. Synthetic… Expand
Is this relevant?
1999
1999
Liarozole Acts Synergistically with 1α,25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity.
1α,25-Dihydroxyvitamin D3[ 1,25-(OH)2D3] inhibits the proliferation of many cancer cells in culture, but not the aggressive human… Expand
  • figure 1
  • figure 4
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
1998
1998
The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin.
The imidazole derivative liarozole is a potent inhibitor of cytochrome P450-dependent 4-hydroxylation of endogenous all-trans… Expand
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells.
We report on the isolation of a cytochrome P450 (CYP)-like retinoic acid (RA) 4-hydroxylase cDNA from T-47D human breast cancer… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • table 1
Is this relevant?
1998
1998
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
OBJECTIVES To compare the efficacy of oral liarozole, the first retinoic acid metabolism-blocking agent (RAMBA) to be developed… Expand
Is this relevant?
Review
1993
Review
1993
Ketoconazole and liarozole in the treatment of advanced prostatic cancer.
BACKGROUND Ketoconazole, an imidazole derivative, is an orally active antifungal agent. In high doses (400 mg three times a day… Expand
Is this relevant?
1992
1992
Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
Liarozole is an imidazole-containing compound that inhibits the cytochrome P-450-dependent metabolism of all-trans-retinoic acid… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE